{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:12:59Z","timestamp":1775077979414,"version":"3.50.1"},"reference-count":70,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JEP"],"DOI":"10.2147\/jep.s259286","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T23:39:23Z","timestamp":1605742763000},"page":"529-538","source":"Crossref","is-referenced-by-count":17,"title":["<p>Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence<\/p>"],"prefix":"10.2147","volume":"Volume 12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0209-6494","authenticated-orcid":true,"given":"Julia","family":"Sellar\u00e8s-Nadal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benito","family":"Almirante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","volume":"386","author":"Prina","year":"2015","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1500245","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1056\/NEJMoa1209165","volume":"369","author":"Griffin","year":"2013","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/cid\/cix647","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cmi.2019.06.025","volume":"26","author":"Bordon","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(03)15021-0","volume":"362","author":"File","year":"2003","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1136\/thorax.56.4.296","volume":"56","author":"Lim","year":"2001","journal-title":"Thorax"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1086\/648678","volume":"50","author":"Johansson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"E45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1183\/16000617.0076-2015","volume":"25","author":"Burk","year":"2016","journal-title":"Eur Respir Rev"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12879-015-0803-5","volume":"15","author":"Holter","year":"2015","journal-title":"BMC Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/cid\/civ1214","volume":"62","author":"Gadsby","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1513\/AnnalsATS.201407-305OC","volume":"12","author":"Prina","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.j2471","volume":"358","author":"Wunderink","year":"2017","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit Care Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09031936.00054108","volume":"33","author":"Restrepo","year":"2009","journal-title":"Eur Respir J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jama.2016.0115","volume":"315","author":"Lee","year":"2016","journal-title":"JAMA - J Am Med Assoc"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","volume":"372","author":"Postma","year":"2015","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388\u2013416. doi:10.1164\/rccm.200405-644ST","DOI":"10.1164\/rccm.200405-644ST"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1093\/jac\/dkr176","volume":"66","author":"Grenier","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MAJ.0b013e3180312cd5","volume":"333","author":"Mufson","year":"2007","journal-title":"Am J Med Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1086\/500140","volume":"42","author":"Tleyjeh","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1086\/598975","volume":"48","author":"Weinstein","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1097\/MJT.0000000000000551","volume":"24","author":"Cherazard","year":"2017","journal-title":"Am J Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2016.00098","volume":"6","author":"Schroeder","year":"2016","journal-title":"Front Cell Infect Microbiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jemermed.2018.04.031","volume":"55","author":"Haran","year":"2018","journal-title":"J Emerg Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/cid\/ciw300","volume":"63","author":"Self","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref30","unstructured":"FDA Drug Safety Communication. FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. FDA. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics. Accessed Jul 6, 2020."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jac\/dkx543","volume":"73","author":"Mogle","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofz514","volume":"7","author":"Horcajada","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"ref33","unstructured":"Melinta Therapeutics announces U.S. FDA approval of supplemental new drug application for BAXDELA\u00ae (delafloxacin) for the treatment of community-acquired bacterial pneumonia (CABP). Melinta Therapeutics, Inc. Available from: http:\/\/ir.melinta.com\/news-releases\/news-release-details\/melinta-therapeutics-announces-us-fda-approval-supplemental-new. Accessed Jul 6, 2020."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/0018578718823730","volume":"54","author":"Baker","year":"2019","journal-title":"Hosp Pharm"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMe1900188","volume":"380","author":"Chambers","year":"2019","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/14656566.2020.1714592","volume":"21","author":"Falc\u00f3","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/cid\/ciz090","volume":"69","author":"File","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.2019.15468","volume":"322","author":"Alexander","year":"2019","journal-title":"JAMA - J Am Med Assoc"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM-JW.NA49805","author":"Sakoulas","year":"2019","journal-title":"NEJM J Watch"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.2147\/DDDT.S119545","volume":"1","author":"Donald","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/cid\/ciw490","volume":"63","author":"File","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref44","unstructured":"FDA Briefing Document. Solithromycin oral capsule and injection meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). November. 2016;4."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1128\/AAC.01808-10","volume":"55","author":"Lai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1128\/AAC.02263-13","volume":"58","author":"Chotikanatis","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/IDR.S193233","volume":"12","author":"Chang","year":"2019","journal-title":"Infect Drug Resist"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jmii.2015.09.005","volume":"50","author":"Liu","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/14656566.2017.1340937.MANAGING","volume":"18","author":"Amalakuhan","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jmii.2017.07.011","volume":"52","author":"Yuan","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1128\/AAC.00295-10","volume":"54","author":"Van Rensburg","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jac\/dkl304","volume":"58","author":"Kwon","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12941-016-0150-4","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref54","unstructured":"Safety and efficacy study of oral zabofloxacin in community-acquired pneumonia. ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01081964?cond=zabofloxacin&draw=2&rank=2. Accessed Jul 17, 2020."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1128\/AAC.01374-09","volume":"54","author":"Morrow","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijantimicag.2011.11.016","volume":"39","author":"Biedenbach","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1093\/jac\/dkt217","volume":"68","author":"Covington","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1128\/AAC.01994-13","volume":"58","author":"Krokidis","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01230-17","volume":"61","author":"Flamm","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01096-17","volume":"61","author":"Rodvold","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref61","unstructured":"Phase II study of oral nafithromycin in CABP - Study results - ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02903836. Accessed Jul 7, 2020."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e00004","DOI":"10.1128\/mSphere.00004-17","volume":"2","author":"Grossman","year":"2017","journal-title":"mSphere"},{"key":"ref63","unstructured":"A Phase 1 study to assess the safety, tolerability and PK of IV TP-271. ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02724085. Accessed Jul 7, 2020."},{"key":"ref64","first-page":"abstr F","author":"Tiffany","year":"2013","journal-title":"Abstr 53rd Intersci Conf Antimicrob Agents Chemother"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1128\/AAC.01724-09","volume":"54","author":"Lemaire","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref66","unstructured":"Safety and efficacy study of oxazolidinone to treat pneumonia. ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00640926?cond=radezolid&draw=2&rank=1. Accessed Jul 7, 2020."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1128\/CMR.00033-13","volume":"26","author":"Pucci","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"ref68","unstructured":"Multiple ascending dose study for LCB01\u20130371. ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01842516. Accessed Jul 7, 2020."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nbt.3037","volume":"33","author":"Henry","year":"2015","journal-title":"Nat Biotechnol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1473-3099(18)30805-3","volume":"19","author":"Laterre","year":"2019","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=63918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=63918","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T23:39:47Z","timestamp":1605742787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/investigational-and-experimental-drugs-for-community-acquired-pneumoni-peer-reviewed-article-JEP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":70,"URL":"https:\/\/doi.org\/10.2147\/jep.s259286","relation":{},"ISSN":["1179-1454"],"issn-type":[{"value":"1179-1454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}